Relative Importance of Complement-mediated Bactericidal and Opsonic Activity for Protection Against Meningococcal Disease

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2009 May 30

PMID 19477054

Citations 37

Authors

Dan M Granoff

Affiliations

Soon will be listed here.

Abstract

Killing of Neisseria meningitidis can result from complement-mediated serum bactericidal activity (SBA) or opsonophagocytosis (OPA), or a combination of the two mechanisms. While SBA titers > or =1:4 confer protection, recent evidence suggests that this threshold titer may not be required. For example, the incidence of meningococcal disease declines between ages 1 and 4 years without evidence of acquisition of SBA titers > or =1:4. Meningococcal polysaccharide vaccination also elicited OPA and lowered the risk of disease in patients with late complement component deficiencies whose sera did not support SBA. Sera from healthy adults immunized with an outer membrane vesicle vaccine showed OPA killing of N. meningitidis with C6-depleted complement, and whole blood from complement-sufficient non-immunized adults with SBA titers <1:4 also frequently had killing activity. Collectively the data indicate that SBA titers <1:4 and/or vaccine-induced OPA can confer protection against meningococcal disease.

Citing Articles

Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions.

McKeague M, Lohmueller J, Dracz M, Saadallah N, Ricci E, Beckwith D Antibodies (Basel). 2024; 13(4.

PMID: 39449327 PMC: 11503386. DOI: 10.3390/antib13040085.

A live attenuated vaccine to prevent severe neonatal Escherichia coli K1 infections.

Sereme Y, Schrimp C, Faury H, Agapoff M, Lefebvre-Wloszczowski E, Chang Marchand Y Nat Commun. 2024; 15(1):3021.

PMID: 38589401 PMC: 11001983. DOI: 10.1038/s41467-024-46775-x.

Low-frequency inherited complement receptor variants are associated with purpura fulminans.

Bendapudi P, Nazeen S, Ryu J, Soylemez O, Robbins A, Rouaisnel B Blood. 2023; 143(11):1032-1044.

PMID: 38096369 PMC: 10950473. DOI: 10.1182/blood.2023021231.

Evaluating vaccine-elicited antibody activities against : cross-protective responses elicited by the 4CMenB meningococcal vaccine.

Gray M, Thomas K, Lamb E, Werner L, Connolly K, Jerse A Infect Immun. 2023; 91(12):e0030923.

PMID: 37991382 PMC: 10715150. DOI: 10.1128/iai.00309-23.

Efficacy and Safety of Quadrivalent Conjugate Meningococcal Vaccines: A Systematic Review and Meta-Analysis.

Conti A, Broglia G, Sacchi C, Risi F, Barone-Adesi F, Panella M Vaccines (Basel). 2023; 11(1).

PMID: 36680022 PMC: 9866575. DOI: 10.3390/vaccines11010178.

References

Fijen C, Kuijper E, Hannema A, Sjoholm A, van Putten J . Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups. Lancet. 1989; 2(8663):585-8. DOI: 10.1016/s0140-6736(89)90712-5. View

Borrow R, Balmer P, Miller E . Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine. 2005; 23(17-18):2222-7. DOI: 10.1016/j.vaccine.2005.01.051. View

Ferriani V, Barbosa J, DE CARVALHO I . Complement haemolytic activity (classical and alternative pathways), C3, C4 and factor B titres in healthy children. Acta Paediatr. 1999; 88(10):1062-6. DOI: 10.1080/08035259950168081. View

Welsch J, Moe G, Rossi R, Adu-Bobie J, Rappuoli R, Granoff D . Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis. 2003; 188(11):1730-40. DOI: 10.1086/379375. View

Trotter C, Findlow J, Balmer P, Holland A, Barchha R, Hamer N . Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin Vaccine Immunol. 2007; 14(7):863-8. PMC: 1951059. DOI: 10.1128/CVI.00102-07. View

Figueroa J, Densen P . Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. 1991; 4(3):359-95. PMC: 358203. DOI: 10.1128/CMR.4.3.359. View

Seib K, Serruto D, Oriente F, Delany I, Adu-Bobie J, Veggi D . Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun. 2008; 77(1):292-9. PMC: 2612274. DOI: 10.1128/IAI.01071-08. View

Fijen C, Kuijper E, Drogari-Apiranthitou M, van Leeuwen Y, Daha M, Dankert J . Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol. 1998; 114(3):362-9. PMC: 1905137. DOI: 10.1046/j.1365-2249.1998.00738.x. View

Zollinger W, Mandrell R . Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun. 1983; 40(1):257-64. PMC: 264843. DOI: 10.1128/iai.40.1.257-264.1983. View

10.

Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel M . Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005; 159(10):907-13. DOI: 10.1001/archpedi.159.10.907. View

11.

Amir J, Louie L, Granoff D . Naturally-acquired immunity to Neisseria meningitidis group A. Vaccine. 2004; 23(8):977-83. DOI: 10.1016/j.vaccine.2004.07.042. View

12.

Ison C, Anwar N, Cole M, Galassini R, Heyderman R, Klein N . Assessment of immune response to meningococcal disease: comparison of a whole-blood assay and the serum bactericidal assay. Microb Pathog. 1999; 27(4):207-14. DOI: 10.1006/mpat.1999.0296. View

13.

de Paula P, Barbosa J, Junior P, Ferriani V, Latorre M, Nudelman V . Ontogeny of complement regulatory proteins - concentrations of factor h, factor I, c4b-binding protein, properdin and vitronectin in healthy children of different ages and in adults. Scand J Immunol. 2003; 58(5):572-7. DOI: 10.1046/j.1365-3083.2003.01326.x. View

14.

Welsch J, Granoff D . Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity. Infect Immun. 2004; 72(10):5903-9. PMC: 517551. DOI: 10.1128/IAI.72.10.5903-5909.2004. View

15.

Platonov A, Vershinina I, Kuijper E, Borrow R, Kayhty H . Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine. 2003; 21(27-30):4437-47. DOI: 10.1016/s0264-410x(03)00440-7. View

16.

Plested J, Granoff D . Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin Vaccine Immunol. 2008; 15(5):799-804. PMC: 2394837. DOI: 10.1128/CVI.00036-08. View

17.

Welsch J, Ram S, Koeberling O, Granoff D . Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis. 2008; 197(7):1053-61. DOI: 10.1086/528994. View

18.

Andreoni J, Kayhty H, Densen P . Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals. J Infect Dis. 1993; 168(1):227-31. DOI: 10.1093/infdis/168.1.227. View

19.

Castagnola E, Fioredda F . Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes. Eur J Haematol. 2003; 71(5):319-26. DOI: 10.1034/j.1600-0609.2003.00158.x. View

20.

Granoff D, Morgan A, Welsch J . Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children. Vaccine. 2005; 23(34):4307-14. DOI: 10.1016/j.vaccine.2005.03.031. View